SomnoMed Limited’s shares are listed on the Australian Securities Exchange.

Annual Reports

2020 Annual Report
2019 Annual Report
2018 Annual Report
2017 Annual Report
2016 Annual Report
2015 Annual Report
2014 Annual Report
2013 Annual Report
2012 Annual Report
2011 Annual Report
2010 Annual Report

ASX announcements – Q2 2021 (October 2020 – December 2020)

SomnoMed Letter To Shareholders Annual General Meeting 2020
Proxy Form

ASX announcements – Q1 2021 (July 2020 – Sept 2020)

SOM Appendix_4C_Q4_FY2020
ASX Announcement Q4 Results July 2020 22.7.20
SOM – Investor conference call and webcast details FY 2020 results
SOM_Preliminary_Accounts_FY20_Final
SomnoMed Investor Presentation FY20
Link to SomnoMed’s 2020 results webcast: http://webcast.boardroom.media/somnomed-limited/20200824/NaN5f28f288ab921a0019e71302
SOM App 3X NVA
SOM App 3X MG
SOM App 3X HB
SOM App 3X AB
SOM App 3X GR
SOM Appendix_03Z RS
SOM Appendix_03Z LA
SOM Appendix_03Z PN
SOM App 3Y Guy Russo
Auditor change
SOM App 3Y Michael Gordon
SOM App 3Y AB
Appendix 4G and Corporate Governance Statement FY20-9.28
Form 605_Somnomed Ltd

ASX announcements – Q4 2020 (April 2020 – June 2020)

Appendix- 02A June 2020
S&P DJI Announces June 2020 Quarterly Rebalance
ASX Trading Update 2 June 2020
Q3 FY20 Results
Appendix 4C Q3 FY2020
Change of Director’s interest Notice
Change of Director’s interest Notice
Change of Director’s interest Notice
Change of Director’s interest Notice
Change in substantial holding
Appendix 2a
Results of Retail Entitlement offer
Change in substantial holding
Change of Director’s Interest Notice
Notification to ineligible shareholders
Retail Entitlement Offer Booklet

ASX announcements – Q3 2020 (January 2020 – March 2020)

Appendix 2a
Results of institutional Offer
Reinstatement to Official Quotation
Cleansing Notice – March 2020
Proposed issue of securities
Investor Presentation March 2020
Trading update and Entitlement offer
Investor Presentation
Half Year Accounts
Core revenue growth up 19% in Q2
Appendix 4C – quarterly
Suspension from Official Quotation

ASX announcements – Q2 2020 (October 2019 - December 2019)

Notice of AGM of SomnoMed 2019
SomnoMed Proxy 2019
Results of Meeting
AGM addresses to Shareholders
SomnoMed Limited signs agreement with App-Nea LLC
Appendix 4C – quarterly
Strong North American revenue growth in Q1

ASX announcements – Q1 2020 (July 2019 - September 2019)
Corporate Governance Statement & Appendix 4G
Annual Report to shareholders
Appointment Sales & Marketing Exec. VP North America
Appendix 3B – Lapse of options
Change of Director’s Interest Notice
ASX announcements – Q4 2019 (April 2019 - June 2019)

SOM Preliminary Accounts FY19
Appendix 4C Q4 FY2019
Investor Presentation FY2019

ASX announcements – Q3 2019 (January 2019 - March 2019)

ASX announcements – Q2 2019 (October 2018 - December 2018)

Appendix 3B 3.10.18 – New issue announcement
Appendix 3B 19th November 2018a
ASX Announcement 19.11 – Change in Leadership of SomnoMed
NVA CEO Key Terms 19.11
ASX Announcement AGM November 2018
AGM 2018 addresses 27.11.18
AGM Results for ASX 2018
Appendix 4C Q2 FY2019

ASX announcements – Q1 2019 (July 2018 - September 2018)

Appendix 3X – Initial Director’s Interest Notice
Appendix 4C Q1 FY2019

ASX Announcements – Q4 2018 (April 2018 - June 2018)

AGM Results for ASX 2018
SomnoMed Proxy 2018
Appendix 4C Q3 FY2019

ASX Announcements – Q3 2018 (January 2018 – March 2018)

SOM Wilsons March 2018
Appendix 3Y Change of Director’s Interest Notice (RS) March 18
Appendix 3Y Change of Director’s Interest Notice (LA) March 18
TDM – Substantial Shareholder Notice 2018.03.22
Shareholding distribution – Analysis of Holdings as at 22-03-2018
SomnoMed – Appendix 3B 22.3.18 Retail Entitlements
Appendix 3Y Change of Director’s Interest Notice Feb 18
Announcement of Dispatch of Entitlement Offer – 26.2.18
SomnoMed – Appendix 3B 27.2.18 Institutional Entitlements
Confirmation of Release – SOM – Ceasing to be a substantial holder from AEF
SomnoMed – Announcement of Entitlement Offer 18.2.18 – Clean
Somnomed – Appendix 3B -19.2.18
SomnoMed – Cleansing Notice 18.2.18 – Clean
SomnoMed – Ineligible Shareholders Letter 18.2.18
Trading Halt – 19 February 2018
SomnoMed – Retail Entitlement Offer Booklet 20.2.18
SomnoMed – Results of Institutional Offer 20.02.18 – ASX Lodgement
SOM Feb 2018 Investors Presentation Final 18.02.18 ASX Lodgement

ASX Announcements – Q2 2018 (October 2017 – December 2017)

ASXQ1 Oct 17 Final Cleana
SomnoMed Appendix 4C September 2017 final
AGM Results for ASX 2017
ASX Announcement Q2 FY18 ASX
SomnoMed Appendix 4C December 2017ASX
AGM Results for ASX 2017
Som Appendix 3B – 5.10.2017
Som Appendix 3Y
Notice of AGM of SomnoMed 2017
SomnoMed Proxy 2017

ASX Announcements – Q1 2018 (July 2017 – September 2017)

SomAppendix 3B12.9.17
TDM Substancial Shareholder Notice SOM 08.09.2017
SomnoMed (SOM) | BUY: RSS network shaping up nicely 28.08.2017

ASX Announcements – Q4 2017 (April 2017 – June 2017)

SomnoMed FY17 Investors Presentation 24.08.2017
SOM Preliminary Accounts FY17 24.08.2017
TDM Substantial Shareholder Notice SOM – 12.5.17
Renew Sleep Solutions well ahead of plan – 26.4.17
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B – 26.4.17

ASX Announcements – Q3 2017 (January 2017 – March 2017)

SomnoMed Sleeping beauty, Morgans CIMB – 23.2.17
SomnoMed HFY17 – 23.2.17

ASX Announcements – Q2 2017 (October 2016 – December 2016)

SomnoMed HY Accounts – 31.12.16
SOM Wilsons October 2016
SomAppendix 3B7.10.16
SomnoMed Proxy 2016
Notice of AGM of SomnoMed 2016

ASX Announcements – Q1 2017 (July 2016 – September 2016)

FDA 510k Approval for SomnoDent – 29.9.16
SomAppendix 3B 1.9.16
TDM SSH 26.8.16 – Form 604, Notice of change of interests of substantial holder
SomAppendix 3B 25.8.16
SOMApp3YPN 26.8.16
Form 605 Neustadt Shares 26.8.16
SomnoMed FY16 Presentation
SOM Preliminary Accounts FY16
Q4 ASX June 2016 Quarter Final
603 Initial Form SomnoMed Ltd – July 2016
SOM Appendix 4C – Quarterly Report for Entities Admitted on the Basis of Commitments
Derek Smith appointed Global CEO of SomnoMed
CEO appointed for new direct to patient business entity

ASX Announcements - Q4 2016 (April 2016 - June 2016)

Wilson HTM Equity Research – SOM – 1 June 2016
Appendix 03Y Change of Director’s Interest Notice June 2016
Appendix 03Y PN Change of Director’s Interest Notice June 2016
Appendix 03Y LA Change of Director’s Interest Notice June 2016
Results of Retail entitlement offer: 1 June 16
Shareholding Info 6.6.2016
Form 604- Notice of change of interests of substantial holder 6 June 2016
SomnoMed – Appendix 3B – 6 June 2016
SomnoMed – Appendix 3B – 13 May 2016
Announcement of Dispatch of Entitlement Offer – May 2016
SomnoMed – Results of Institutional Offer – FINAL May 2016
SomnoMed – Ineligible Shareholders Letter – May 2016
Announcement of Entitlement Offer – May 2016
Cleansing Notice – May 2016
SOM Investors Presentation FINAL May 2016
SOM Chair Letter May 2016
SOM- Appendix 3B – May 2016
SomnoMed – Ineligible Shareholders Letter – May 2016
SOM Appendix 3B – April 2016

ASX Announcements - Q3 2016 (January 2016 - March 2016)

SOM Appendix  4C – March 2016
SomnoMed HY Accounts at 31 December 2015
SOM Investor Presentation February 2016
SOMNOMED RECORDS 30% GROWTH IN DIRECT SALES REVENUES OF SOMNODENT® DEVICES IN 1ST HALF OF 2015/16
SOM Appendix 4C
Becoming a substantial holder

ASX Announcements - Q2 2016 (October 2015 - December 2015)

FROST & SULLIVAN RECOGNISES SOMNOMED LIMITED AS OBSTRUCTIVE SLEEP APNEA COMPANY OF THE YEAR AT THE ANNUAL AUSTRALIAN EXCELLENCE AWARDS
Appendix 3YPN
AGM Results for ASX 2015
SOM Appendix 3B
SOM Appendix 3B6
SomnoMed acquires Strong Dental, Canada
SOM Appendix 3YLA
SOM Appendix 3YPN
SOM Appendix 3B
SomnoMed exceeds 250,000 patients
SomnoMed  Proxy 2015
Notice of AGM  of SomnoMed 2015
SOM Appendix 3B
GROWTH ACCELERATION IN THE US LEADS TO NEW RECORD QUARTER

ASX Announcements - Q1 2016 (July 2015 - September 2015)

Preliminary Final report 2015
SomnoMed Investor Presentation August 2015 ASX Release
SOM Appendix 4C
SomnoMed Appendix 4G September 2015
New Investor Form 603_090915
SomnoMed Appendix 3B_July 2015
SomnoMed Announcement – Strong Finish to Financial Year – July 2015

ASX Announcements - Q4 2015 (April 2015 - June 2015)

SomnoMed Appendix 4C June 2015 Quarter
DentitracFDA ASX Jun2015
Ceasing to be a Substantial holder_July 2015
SomnoMed Update May 2015
Announcement: SOMNOMED TO ACQUIRE 100% OF SMH BIOMATERIAL AG 
Appendix 3B

ASX Announcements - Q3 2015 (January 2015 - March 2015)

Continuous Growth of SomnoMed in Third Quarter
Appendix 4C Quarterly (Q3)
Ceasing to be a substantial shareholder
Addition of SomnoMed to Australian All Ordinaries Index 
Ceasing to be a substantial shareholder
Appendix 3B New issue announcement
Appendix 4D and Half-Year Financial Review
Investor Presentation: Financial Year 2014-2015 Half Year Review
SomnoMed Achieves Growth Targets
Appendix 3B New Issue Announcement January 2015
Appendix 4C Quarterly

ASX Announcements - Q2 2015 (October 2014 - December 2014)

Form 604 TDM Asset Management December 2014
Appendix 3B New Issue Announcement December 2014
Appendix 3YRS December 2014 – Change of Director’s Interest Notice
Appendix 3YLA – Change of Director’s Interest Notice
Appendix 3YPN – Change of Director’s Interest Notice
Appendix 3YRS – Change of Director’s Interest Notice
Form 604 Belgove December 2014
Appendix 3B New Issue Announcement: application for quotation of additional securities and agreement
Annual Meeting Minutes
SOM Shareholder Change Form Form 604
SomnoMed Exceeds 200,000 Patients
ASX Investor Presentation November 2014
SomnoMed Limited (SOM) Q1 Stock Analysis, Morgans CIMB
SomnoMed Limited (SOM) Q1 Stock Analysis, Wilson HTM
Notice of Annual General Meeting
SomnoMed Limited Proxy Form
Appendix 3B – New issue announcement,application for quotation of additional securities and agreement
New Records in September Confirm Guidance (ASX:SOM)
Appendix 4C – Quarterly report for entities admitted on the basis of commitments 

ASX Announcements - Q1 2015 (July 2014 - September 2014)

US Medicare reimbursement approval granted for SOMNODENT® Herbst Advance
Appendix 3B New issue announcement
SOM:ASX 2014 SHARE PURCHASE PLAN – CLOSES OVERSUBSCRIBED
SomnoMed (”SOM”-ASX) Preliminary final report – 30 June 2014
SOM – Investor Presentation FY14
Appendix 3YLA – Change of Director’s Interest Notice
Appendix 3Y – Change of Director’s Interest Notice
SOM – Change in Substantial Holding
SomnoMed (”SOM”-ASX) Share Placement Update
SomnoMed SOM 708A Cleansing
SomnoMed Limited Appendix 3B – New Issue Announcement
SomnoMed (SOM) Research
SomnoMed Italy

ASX Announcements - Q4 2014 (April 2014 - June 2014)

Appendix 3B_New Issue Annoucement_June 2014
SomnoMed Appendix 4C_June 2014
SomnoMed Q4 Final
SomnoDent Fusion 510k_June 14
SomnoMed Launches New Products at AADSM
SomnoMed – Spain
SomnoMed Enters the UK
Appendix 3B_New Issue Announcement
Form 604_Notice of Change of interests of substantial holder

ASX Announcements – Q3 2014 (January 2014-March 2014)

Appendix 4C_Quarterly report
Notice of ceasing to be a substantial holder
Notice of change of interest of substantial holder
SomnoMed Growth_Q3
Notice of ceasing to be a substantial holder
SomnoMed Growth_Q3

ASX Announcements – Q2 2014 (October 2013-December 2013)

Appendix 3B_New Issue Announcement
Appendix 3B_New Issue announcement
Appendix 3Y_Change of Director’s Interest
Appendix 4C_Quarterly Report
C
ontinuing Global Growth for SomnoMed
Exclusive Agreement Signed for Compliance Measurement
SomnoMed Acquired 2nd Largest OA Company in France
SomnoMed General Meeting_Nov12

ASX Announcements – Q1 2014 (July 2013-September 2013)

Appointment of New US Head
Appointment of new VP managed care
Burkhart Partnership Announcement
SomnoMed Continues to break records in 4th quarter
Appendix 3B New Issue Announcement
Appendix 4C Quarterly Report
SomInvestor Presentation Sept 2012 FINAL
Preliminary Final Report

Every State in the United States of America, and most countries throughout the world have their own laws regulating the types of securities and other investment products which maybe offered to their residents, as well as the process for doing so. As a result, investment in some securities is not available to every interested investor. Accordingly, this information is provided for informational purposes only, and does not constitute an offer or solicitation to buy or sell Somnomed Limited shares in any jurisdiction where such would be prohibited.

All investments involve different degrees of risk. In making any investment you should be aware of your risk tolerance level and financial situations at all times. Furthermore, you should seek professional investment advice before making any investment decisions. Somnomed Limited and/or its shareholders, directors, officers and/or employees make no investment recommendations in respect to any investment made in Somnomed Limited.